Tedavi Dekompanse Kalp Yetersizliğinde Lipit Peroksidasyonunu Azaltmaz
Giriş
Literatürde lipit peroksidasyonunun kalp yetersizliğinde (KY) arttığı gösterilmiş ancak dekompanse kalp
yetersizliğinde (DKY) durumu hala açık değildir. Bu yüzden çalışmanın amacı, dekompanse kalp
yetersizliğinde lipit hidroperoksit'in (LOOH) serum düzeyini ve tedavinin LOOH düzeyleri üzerine etkisini
araştırmaktır.
Materyal ve Metod
Bu amaçla 50 DKYnedeni ile koroner yoğun bakım ünitesine yatan ve sonrasında kompansasyon sağlanarak
taburcu edilen hastalar (kompanse KY(KKY)) ve yaş ve cinsiyet özellikleri benzer kalp yetersizliği olmayan
50 sağlıklı gönüllü çalışmaya dahil edildi. Örnekler hastaların ve sağlıklı kontrollerin her ikisinin kan
damarlarından alındıktan sonra santrifüj edildi. Sonra, LOOH düzeyleri enzimatik bir metotla elde edilen
serumlarda çalışıldı.
Bulgular
En yüksek LOOH düzeyleri KKY grubunda en düşük LOOH düzeyleri kontrol grubunda idi. Ek olarak,
LOOH düzeyleri, DKY grubunda kontrollere göre belirgin olarak yüksekti (p<0,0001) ve KKY grubunda
DKY grubuna ve kontrollere göre de anlamlı derecede yüksekti (p<0,0001). Korelasyon analizinde LOOH
düzeyleri ile yaş, sistolik ve diastolik kan basıncı, serum glikozu ve troponin T düzeyleri, LV diastolik ve
sistolik çapları ile mitral yetersizliği varlığı pozitif olarak, ejeksiyon fraksiyonu ile negatif bir şekilde ilişkili
idi. Lineer regresyon analizi bu parametrelerden sadece açlık kan şekerinin LOOH'u bağımsız olarak
etkilediğini gösterdi.
Sonuç
Sonuç olarak akut DKY hastalarında LOOH yüksekti. Bu yükseklik hastaların yatırılarak kompansasyon
sağlanmasına rağmen azalmamaktaydı.
Treatment Does Not Decrease Lipid Peroxidation In Decompansated Heart Failure
Background
In literature, increased lipid peroxidation in heart failure (HF) has been demostrated, however, it is stil not
clear in the decompensated heart failure (DHF). The aim of this study, hence, is to investigate serum lipid
hydroperoxide (LOOH) levels in the DHF patients and the effect of DHF treatment on serum LOOH levels.
Materials and Methods
For our experiment, 50 patients, who are DHF patients admitted to coroner intensive care unit and discharged
patients providing compansation after their hospitalisation, and 50 healty volunteers, whose age and gender
are similar to the 50 patients, were included. After samples venupunctured from blood vessel of both these
patients and healty volunteers, they were sentrifugated. Afterwards, LOOH levels were studied in the
obtained serums using an enzimatical method.
Results
The highest LOOH levels were in CHF group, and the lowest LOOH levels were in the control group.
Additionally, LOOH levels were significantly in DHF patients higher than in the the controls (p <0.0001),
and were significantly higher in the CHF group compared to both the DHF and control group (p <0.0001). In
the correlation analyses, LOOH levels were possitively correlated with the different parameters such as age,
systolic and diastolic blood pressures, serum glucose and troponin T levels, the left ventricule diastolic and
systolic diameters in the positive presence of mitral regurgitation, but negatifly correlated with the ejection
fraction. Linear regression analysis showed that only glucose level among these parameters affects the
LOOH levels independently.
Conclusions
As a result, LOOH levels elaveted in acute DHF patients. This elevation did not decrease after
treatment,which provides compansation, of the hospitalized patients.
___
- 1. Heart disease and stroke statistics--2010 update: a
report from the American Heart Association.
Circulation. 2010;121(7):e46-e215.
- 2. Heart failure in the 21st century: a cardiogeriatric
syndrome. Rich MW J Gerontol A Biol Sci Med Sci.
2001;56(2):M88-96.
- 3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ,
Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term
trends in the incidence of and survival with heart failure.
N Engl J Med. 2002;347(18):1397-402.
- 4. Stewart S, MacIntyre K, Hole DJ, Capewell S,
McMurray JJ. More 'malignant' than cancer? Five-year
survival following a first admission for heart failure.
Eur J Heart Fail. 2001;3(3):315-22.
- 5. Fang J, Mensah GA, Croft JB, Keenan NL. Heart
failure-related hospitalization in the U.S., 1979 to 2004.
J Am Coll Cardiol. 2008;52(6):428-34.
- 6. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW,
Boscardin WJ, ADHERE Scientific Advisory
Committee, Study Group, and Investigators. Risk
stratification for in-hospital mortality in acutely
decompensated heart failure: classification and
regression tree analysis. JAMA. 2005;293(5):572-80.
- 7. Imai H. [Biological significance of lipid
hydroperoxide and its reducing enzyme, phospholipid
hydroperoxide glutathione peroxidase, in mammalian
cells]. Yakugaku Zasshi. 2004;124(12):937-57.
- 8. Marnett LJ. Lipid peroxidation-DNA damage by
malondialdehyde. Mutat Res. 1999;424(1-2):83-95.
- 9. Friedewald WT, Levy RI, Fredrickson DS. Estimation
of the concentration of low-density lipoprotein
cholesterol in plasma, without use of the preparative
ultracentrifuge. Clin Chem 1972;18:499-502.
- 10. Nourooz Zadeh J. Ferrous ion oxidation in presence
of xylenol orange for detection of lipid hydroperoxides
in plasma. Methods Enzymol 1999;300:58–62.
- 11. ACC/AHAGuidelines for the Clinical Application of
Echocardiography. Circulation. 1997;95:1686-1744.
- 12. Teichholz LE, Kreulen T, Herman MV, Gorlin R.
Problems in echocardiographic volume determinations:
Echocardiographic– angiographic correlations in the
presence of absence of asynergy. Am J Cardiol
1976;37:7–11.
- 13. Blair IA. Lipid hydroperoxide-mediated DNA
damage. Exp Gerontol. 2001;36(9):1473-81.
- 14. Wang TG, Gotoh Y, Jennings MH, Rhoads CA, Aw
TY. Lipid hydroperoxide-induced apoptosis in human
colonic CaCo-2 cells is associated with an early loss of
cellular redox balance. FASEB J. 2000;14(11):1567-76.
- 15. Yanagawa K, Takeda H, Egashira T, Sakai K, Takasaki
M, Matsumiya T. Age-related changes in alphatocopherol
dynamics with relation to lipid hydroperoxide
content and fluidity of rat erythrocyte membrane. J
Gerontol ABiol Sci Med Sci. 1999;54(9):B379-83.
- 16. Sugihara N, Arakawa T, Ohnishi M, Furuno K. Antiand
pro-oxidative effects of flavonoids on metal-induced
lipid hydroperoxide-dependent lipid peroxidation in
cultured hepatocytes loaded with alpha-linolenic acid.
Free Radic Biol Med. 1999;27(11-12):1313-23.
- 17. Montoro-García S, Shantsila E, Wrigley BJ, Tapp LD,
Abellán Alemán J, Lip GY. Small-size Microparticles as
Indicators of Acute Decompensated State in Ischemic
Heart Failure. Rev Esp Cardiol (Engl Ed). 2015 Mar 25.
- 18. Hashem SI, Perry CN, Bauer M, Han S, Clegg SD,
Ouyang K, Deacon DC, Spinharney M, Panopoulos AD,
Izpisua Belmonte JC, Frazer KA, Chen J, Gong Q, Zhou
Z, Chi NC, Adler ED. Oxidative Stress Mediates
Cardiomyocyte Apoptosis in a Human Model of Danon
Disease and Heart Failure. Stem Cells. 2015 Mar 31.
- 19. La Vecchia L, Mezzena G, Zanolla L, Paccanaro M,
Varotto L, Bonanno C, Ometto R. Cardiac troponin I as
diagnostic and prognostic marker in severe heart failure. J
Heart Lung Transplant. 2000;19(7):644-52.
- 20. Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama
T, Okada H, Kataoka K, Ito H, Matsumori A, Sasayama S,
Takatsu Y. Persistently increased serum concentrations of
cardiac troponin-t in patients with idiopathic dilated
cardiomyopathy are predictive of adverse outcomes.
Circulation. 2001;103(3):369-74.
- 21. Cheng W, Li B, Kajstura J, Li P, Wolin MS,
Sonnenblick EH, Hintze TH, Olivetti G, Anversa P.
Stretch-induced programmed myocyte cell death. J Clin
Invest. 1995;96(5):2247-59.
- 22. Anversa P, Kajstura J. Myocyte cell death in the diseased
heart. Circ Res. 1998;82(11):1231-3.
- 23. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W,
Nitahara JA, Quaini E, Di Loreto C, Beltrami CA,
Krajewski S, Reed JC, Anversa P. Apoptosis in the failing
human heart. N Engl J Med. 1997;336(16):1131-41.
- 24. Logeart D, Beyne P, Cusson C, Tokmakova M, Leban
M, Guiti C, Bourgoin P, Solal AC. Evidence of cardiac
myolysis in severe nonischemic heart failure and the
potential role of increased wall strain. Am Heart J.
2001;141(2):247-53.
- 25. Moe GW, Marin-Garcia J, Konig A, Goldenthal M, Lu
X, Feng Q. In vivo TNF-alpha inhibition ameliorates
cardiac mitochondrial dysfunction, oxidative stress, and
apoptosis in experimental heart failure. Am J Physiol Heart
Circ Physiol. 2004;287(4):H1813-20.
- 26. Dalla Libera L, Sabbadini R, Renken C, Ravara B,
Sandri M, Betto R, Angelini A, Vescovo G. Apoptosis in the
skeletal muscle of rats with heart failure is associated with
increased serum levels of TNF-alpha and sphingosine. J
Mol Cell Cardiol. 2001;33(10):1871-8.
- 27. Ueda T, Ueda T, Fukuda S, Browne R, Jenis E, Spengler
R, Chou R, Buch P, Aljada A, Dandona P, Sasisekharan R,
Dorey CK, Armstrong D. Lipid hydroperoxide-induced
tumor necrosis factor (TNF)-alpha, vascular endothelial
growth factor and neovascularization in the rabbit cornea:
effect of TNF inhibition. Angiogenesis. 1998;1(2):174-184.
- 28. Blair IA. Lipid hydroperoxide-mediated DNA damage.
Exp Gerontol. 2001;36(9):1473-81.
- 29. Campolo J, De Maria R, Caruso R, Accinni R, Turazza F,
Parolini M, Roubina E, De Chiara B, Cighetti G, Frigerio
M, Vitali E, Parodi O. Blood glutathione as independent
marker of lipid peroxidation in heart failure. Int J Cardiol.
2007;117(1):45-50.
- 30. Varga ZV, Giricz Z, Liaudet L, Haskó G, Ferdinandy P,
Pacher P. Interplay of oxidative, nitrosative/nitrative stress,
inflammation, cell death and autophagy in diabetic
c a r d i o m y o p a t h y. B i o c h i m B i o p h y s A c t a .
2015;1852(2):232-42.
- 31. Pall ML. The NO/ONOO-cycle as the central cause of
heart failure. Int J Mol Sci. 2013;14(11):22274-330.